Holen Sie sich die Stockscreener-App
47.46
5.04%
-2.57
Überblick
Nachrichten
Preisverlauf
Optionskette
Warum fällt NVO?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$50.03
Offen:
$48.96
24-Stunden-Volumen:
40.61M
Relative Volume:
3.35
Marktkapitalisierung:
$161.00B
Einnahmen:
$43.59B
Nettoeinkommen (Verlust:
$15.04B
KGV:
14.06
EPS:
3.3766
Netto-Cashflow:
$10.74B
1W Leistung:
-32.83%
1M Leistung:
-31.17%
6M Leistung:
-43.74%
1J Leistung:
-64.18%
1-Tages-Spanne:
$47.42
$49.30
1-Wochen-Bereich:
$47.42
$71.80
52-Wochen-Spanne:
$47.42
$139.74
Novo Nordisk Adr Stock (NVO) Company Profile
Vergleichen Sie NVO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NVO
Novo Nordisk Adr
|
47.49 | 239.68B | 43.59B | 15.04B | 10.74B | 3.3766 |
|
LLY
Lilly Eli Co
|
743.43 | 684.93B | 49.00B | 11.11B | -1.27B | 12.29 |
|
JNJ
Johnson Johnson
|
165.43 | 404.87B | 90.63B | 22.66B | 16.40B | 9.35 |
|
ABBV
Abbvie Inc
|
191.28 | 337.77B | 57.37B | 4.20B | 15.39B | 2.35 |
|
NVS
Novartis Ag Adr
|
114.08 | 226.92B | 55.19B | 13.65B | 16.81B | 6.86 |
|
MRK
Merck Co Inc
|
78.56 | 207.49B | 63.62B | 16.41B | 17.04B | 6.49 |
Novo Nordisk Adr Stock (NVO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-30 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2025-04-17 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2025-03-13 | Hochstufung | Kepler | Hold → Buy |
| 2025-03-03 | Herabstufung | Stifel | Buy → Hold |
| 2025-02-12 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2025-01-06 | Hochstufung | Bernstein | Underperform → Mkt Perform |
| 2024-05-30 | Eingeleitet | Goldman | Buy |
| 2024-04-12 | Eingeleitet | BMO Capital Markets | Outperform |
| 2024-01-23 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-01-16 | Fortgesetzt | UBS | Neutral |
| 2023-12-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-10-02 | Eingeleitet | Argus | Buy |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2022-07-15 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-06-28 | Herabstufung | UBS | Neutral → Sell |
| 2022-06-27 | Hochstufung | Exane BNP Paribas | Underperform → Neutral |
| 2022-06-07 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-05-31 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-04-25 | Hochstufung | Cowen | Market Perform → Outperform |
| 2022-04-12 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2022-03-16 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2022-01-25 | Herabstufung | Liberum | Hold → Sell |
| 2021-12-20 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-12-17 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2021-01-20 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2021-01-15 | Eingeleitet | Deutsche Bank | Buy |
| 2020-09-29 | Eingeleitet | Berenberg | Hold |
| 2020-07-06 | Herabstufung | BofA Securities | Buy → Neutral |
| 2020-05-11 | Herabstufung | UBS | Buy → Neutral |
| 2020-05-04 | Eingeleitet | Cowen | Market Perform |
| 2020-03-16 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2020-01-03 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-11-18 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2019-09-17 | Hochstufung | Citigroup | Neutral → Buy |
| 2019-08-30 | Herabstufung | Jefferies | Hold → Underperform |
| 2019-06-20 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2019-06-11 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2019-04-29 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2019-01-29 | Eingeleitet | Exane BNP Paribas | Outperform |
| 2018-12-11 | Fortgesetzt | Jefferies | Hold |
| 2018-10-09 | Eingeleitet | Guggenheim | Buy |
| 2017-12-29 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2017-12-06 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2017-12-01 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2017-09-25 | Herabstufung | Exane BNP Paribas | Outperform → Neutral |
| 2017-09-06 | Hochstufung | BofA/Merrill | Underperform → Neutral |
Alle ansehen
Novo Nordisk Adr Aktie (NVO) Neueste Nachrichten
Novo Nordisk: Is the Ozempic Hype Train Finally Slowing Down? - Investing.com
Is Novo Nordisk A s (b Shares) Adrhedged stock overvalued or undervaluedExpert Picks Outlook To Watch Now - jammulinksnews.com
Earnings visualization tools for Novo Nordisk A s (b Shares) AdrhedgedSwing Trade Watchlist with Entry Zones - Newser
Why Novo Nordisk A s (b Shares) Adrhedged stock attracts strong analyst attentionIntraday Price Action Forecast Planner - Newser
Will Novo Nordisk A s (b Shares) Adrhedged benefit from macro trendsFree Oversold Recovery Opportunity Stocks - Newser
Real time scanner hits for Novo Nordisk A s (b Shares) Adrhedged explainedStep-by-Step Stock Investment Guide Gains Popularity - metal.it
Will earnings trigger a reversal in Novo Nordisk A s (b Shares) AdrhedgedFree News Based Entry Opportunity Alerts - Newser
Using AI based signals to follow Novo Nordisk A s (b Shares) AdrhedgedTrading Volume Spike and Reversal Analysis - Newser
How to monitor Novo Nordisk A s (b Shares) Adrhedged with trend dashboardsFree Stock Selection With High Accuracy - Newser
Is Novo Nordisk A s (b Shares) Adrhedged trending in predictive chart modelsFree Consistent Profit Pattern Recognition Tools - Newser
Will Novo Nordisk A s (b Shares) Adrhedged Benefit From Broader Market BounceTriple Return Setup With Risk Control Explained - metal.it
HIMS & HERS HEALTH SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuits Against Hims & Hers Health, Inc. - GlobeNewswire Inc.
Novo Nordisk Falls On Lowered Guidance. Pharma Giant Names New CEO. - Investor's Business Daily
Novo Nordisk ADR: Navigating Market Fluctuations with a 181.64B Market Cap - investchronicle.com
Bollinger Bands Show Potential Breakout in Novo Nordisk A s (b Shares) AdrhedgedProfit Target Stock Opportunity Monitor Activated - metal.it
Novo Nordisk Slumps While Philips Shines In European ADRs - Finimize
Novo Nordisk: Lower 2025 Guidance Reflects Persistent Competition From Compounded Semaglutide - Morningstar
Novo Nordisk: Lower 2025 Guidance Reflects Persistent Competition from Compounded Semaglutide - Morningstar
Novo Nordisk's Cardiometabolic Portfolio, Led by Semaglutide, Looks Underappreciated - Morningstar
Wall Street Today: Nasdaq, S&P hit record high; Sofi, Novo Nordisk, UnitedHealth shares in focus after Q2 results - Mint
Here’s What Happened The Last Time Novo Nordisk Stock Was This Oversold - Barchart.com
Published on: 2025-07-29 13:38:20 - metal.it
What institutional investors are buying Novo Nordisk A s (b Shares) Adrhedged stockLow Risk Forecasts For Smart Trading - jammulinksnews.com
How many analysts rate Novo Nordisk A s (b Shares) Adrhedged as a “Buy”Value Investing Entry Points With Proven Results - jammulinksnews.com
Published on: 2025-07-28 18:52:29 - beatles.ru
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Hims & Hers Health, Inc. of Class Action Lawsuit and Upcoming Deadlines - GlobeNewswire Inc.
Is Novo Nordisk A s (b Shares) Adrhedged Stock a Smart Buy in 2025 Investment Analysis InsideDaily Market Momentum Summary and Strategy - Newser
Quhuo Ltd ADR Plunges 49.7% on Revenue Decline - AInvest
New Product Launches: Will They Boost Novo Nordisk A s (b Shares) Adrhedged Stock in 2025Stock Market Watch with Smart Filters - Newser
Tick level data insight on Novo Nordisk A s (b Shares) Adrhedged volatilityBear Market Safe Zone Technical Analysis - Newser
How strong is Novo Nordisk A s (b Shares) Adrhedged company’s balance sheetUnlock powerful market trend analysis - jammulinksnews.com
What is the risk reward ratio of investing in Novo Nordisk A s (b Shares) Adrhedged stock - jammulinksnews.com
How does Novo Nordisk A s (b Shares) Adrhedged compare to its industry peersCapitalize on fast-growing investment opportunities - jammulinksnews.com
Published on: 2025-07-27 16:50:09 - jammulinksnews.com
NVO Stock Quote Price and Forecast - CNN
Hims & Hers Health, Inc. Sued for Securities Law Violations - GlobeNewswire Inc.
HIMS & HERS HEALTH SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuits Against Hims & Hers Health, Inc. - GlobeNewswire Inc.
European ADRs Inch Higher As Drugmakers Shine - Finimize
Finanzdaten der Novo Nordisk Adr-Aktie (NVO)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.58%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):